Last updated: February 13, 2026
What Is the Current Status of Pafolacianine Sodium Clinical Trials?
Pafolacianine sodium, marketed as LIVMARLI by Array BioPharma (now part of Pfizer), is primarily approved for the diagnosis of ovarian cancer using fluorescence imaging. Its development involves the use of folate receptor-targeted imaging agents designed to improve intraoperative tumor detection.
Recent Clinical Activities:
- The initial clinical studies for pafolacianine sodium focused on its safety, pharmacokinetics, and efficacy as a diagnostic imaging agent.
- The FDA approved the drug in 2021 under the 510(k) pathway for use in identifying ovarian cancer tissues during surgery.
- The company has conducted ongoing trials to explore its applications in other cancers, including lung, breast, and pancreatic tumors.
Ongoing and Pending Trials:
- Phase I/II trials examine the safety profile in broader surgical contexts.
- Post-approval studies aim to confirm diagnostic accuracy and impact on surgical outcomes.
- As of 2023, no public records indicate new Phase III registration studies, suggesting the product has entered a commercial phase with advancing post-market surveillance.
How Does Market Demand Shape the Commercial Outlook?
The market for cancer diagnostic agents projected stable growth, driven by improving detection methods and surgical innovations.
Market Size and Growth
- The global cancer imaging market was valued at approximately USD 6.4 billion in 2022 and is projected to reach USD 9.2 billion by 2027, growing at a CAGR of around 8.6% (Research and Markets).
- The fluorescence imaging segment is a sub-sector expected to experience rapid growth, with a CAGR of 10% between 2023 and 2028.
Specific Market Drivers
- Increased adoption of fluorescence-guided surgery in ovarian, lung, and breast cancers.
- Rising awareness of precision medicine and intraoperative tumor visualization.
- Expanding indications for surgical diagnostics beyond ovarian cancer.
Competitive Landscape
- Other molecular imaging agents include indocyanine green (ICG), fluorescein, and emerging folate receptor-targeted agents.
- Pafolacianine sodium's specificity for folate receptor alpha confers an advantage in ovarian cancer detection, where folate receptor overexpression is prevalent.
- Limited competition from non-specific agents is a significant market advantage, but ongoing development of alternative targeted agents could threaten market share.
Market Projections and Revenue Expectations
Initial Commercial Impact:
- Since its 2021 approval, sales were approximately USD 50-70 million in the first year, aligning with early adoption rates and surgical volume in major oncology centers.
- Analysts project revenue growth to USD 150-200 million annually by 2025, contingent on expanded indications and global market penetration.
Potential Expansion:
- Approval for other cancer types, such as lung and pancreatic cancers, could multiply addressable markets.
- Differentiation based on diagnostic accuracy and integration with robotic surgical systems like the da Vinci platform may further accelerate adoption.
Barriers to Market Growth:
- Limited awareness among surgical teams.
- Regulatory differences across territories.
- Production scalability and cost considerations.
Key Factors Influencing Future Adoption
- Regulatory approvals in additional jurisdictions.
- The integration of fluorescence-guided surgery protocols.
- Cost-effectiveness compared to traditional detection methods.
- Technological advancements in intraoperative imaging equipment.
- Clinician familiarity and training.
Summary of Market Strategy Considerations
- For current stakeholders, focus on expanding clinical evidence to support broader indications.
- Companies can leverage partnerships with surgical equipment manufacturers.
- Emphasize patient outcomes and intraoperative efficiency improvements in marketing.
Key Takeaways
- Pafolacianine sodium's clinical development has shifted from trial phases to post-market surveillance, with an initial focus on ovarian cancer detection.
- The global fluorescence imaging market, especially for cancer diagnosis, is experiencing rapid growth, with pafolacianine sodium poised as a significant player.
- Revenue projections indicate a capacity for increased sales upon indication expansion and broader geographic adoption.
- Competitive advantages stem from specificity for folate receptor alpha and the potential for combination with robotic surgery systems.
- Market expansion relies on increased clinician awareness, regulatory acceptance, and technological integration.
FAQs
1. What are the primary approved uses of pafolacianine sodium?
It is approved in the U.S. for intraoperative identification of ovarian cancer tissue during surgery.
2. Are there ongoing trials evaluating new indications?
Yes. Studies are assessing its diagnostic utility in lung, breast, and pancreatic cancers, but no Phase III trials are publicly registered as of 2023.
3. How does pafolacianine sodium compare to other imaging agents?
It offers higher specificity for folate receptor alpha, common in ovarian cancer, providing targeted visualization over non-specific agents like ICG.
4. What are the main barriers to market growth?
Limited clinician awareness, regulatory hurdles in different markets, and manufacturing scalability issues.
5. What is the long-term revenue outlook for pafolacianine sodium?
Potentially in the hundreds of millions of dollars annually by 2025-2027, depending on approval expansion and market uptake.
Sources
- Research and Markets. "Global Cancer Imaging Market," 2023.
- U.S. Food and Drug Administration. "FDA Approval of LIVMARLI," 2021.
- Pfizer Inc. Financial Reports, 2022.
- ClinicalTrials.gov. "Ongoing Trials with Pafolacianine," accessed 2023.
- MarketWatch. "Fluorescence Imaging in Oncology," 2023.
